行情

BOLD

BOLD

Audentes
NASDAQ

实时行情|Nasdaq Last Sale

59.97
-0.01
-0.02%
已退市 09:30 01/17 EST
开盘
59.98
昨收
59.98
最高
59.99
最低
59.97
成交量
215.23万
成交额
--
52周最高
60.00
52周最低
22.00
市值
27.46亿
市盈率(TTM)
-15.0584
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BOLD 新闻

  • 2019 Review: Most Favored Hedge Fund Stocks vs. Audentes Therapeutics, Inc. (BOLD)
  • Insider Monkey.01/12 22:38
  • AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down
  • Zacks.01/10 23:08
  • Agenus Initiates Phase I Study on Oncology Candidate AGEN1223
  • Zacks.01/09 14:48
  • The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering
  • Benzinga.01/07 12:57

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

BOLD 简况

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.
展开

Webull提供Audentes Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。